Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Improved survival with fludarabine-based therapies in mixed phenotype acute leukaemia: A population-based study using the WHO 2022 classification.

British journal of haematology - 1 Jun 2026

Christensen Lisa-Maj, Simonsen Mikkel Runason, Jensen Jonas Faartoft, Kristensen Daniel Tuyet, Dybkær Karen, Grønbæk Kirsten, El-Galaly Tarec Christoffer, Ettrup Marianne Schmidt, Ommen Hans Beier, Sørensen Anne Louise Tølbøll, Hansen Dennis Lund, Severinsen Marianne Tang

Abstract excerpt

Mixed phenotype acute leukaemia (MPAL) is a rare subtype of acute leukaemia possessing significant therapeutic challenges, as no standardized, evidence-based treatment regimen has been defined. In this nationwide study, we aimed to assess the effect of an acute lymphoid leukaemia (ALL)-like regimen; an acute myeloid leukaemia (AML)-like regimen; and a hybrid regimen on complete remission (CR), overall survival...

Topics

Join the communities discussing this publication.

Aged
Antineoplastic Combined Chemotherapy Protocols
Cytarabine
Denmark

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Leukemia, Myeloid, Acute

Source

Open in PubMed Open full text

Identifiers

PMID: 41992976
DOI: 10.1111/bjh.70491
PMCID: PMC13267474

Genes

EFS

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 1 Sept 2026.

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

0

discussions

0

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Improved survival with fludarabine-based therapies in mixed phenotype acute leukaemia: A population-based study using the WHO 2022 classification.PMID 41992976Read ↗

Mixed Phenotype/Lineage Leukemia: Has Anything Changed for 2021 on Diagnosis, Classification, and Treatment?Semantic proximity Read ↗

Exploring mixed phenotype acute leukemia: Clinical, immunophenotypic, cytogenetic, and prognostic insights from a tertiary care center.Semantic proximity Read ↗

Outcomes with high dose cytarabine and mitoxantrone induction for adults with mixed phenotype acute leukemia.Semantic proximity Read ↗

Unmanipulated haploidentical hematopoietic stem cell transplantation for mixed phenotype acute leukemia: a single center studySemantic proximity Read ↗

Acute myeloid leukemia: Treatment and research outlook for 2021 and the MD Anderson approach.Semantic proximity Read ↗

Mixed-Phenotype Acute Leukemia: Clinical Diagnosis and Therapeutic StrategiesSemantic proximity Read ↗

Acute lymphoblastic leukemia-like treatment regimen provides better response in mixed phenotype acute leukemia: a comparative study between adults and pediatric MPAL patients.Semantic proximity Read ↗

Comparison of the 2022 and 2017 European LeukemiaNet risk classifications in a real-life cohort of the PETHEMA group.Semantic proximity Read ↗

[Diagnosis and treatment efficacy analysis of 29 children with mixed phenotype acute leukemia].Semantic proximity Read ↗

Mixed phenotype acute leukemia: outcomes with allogeneic stem cell transplantation. A retrospective study from the Acute Leukemia Working Party of the EBMT.Semantic proximity Read ↗

Characteristics, outcomes and treatment patterns in acute myeloid leukemia patients 60 Years or older in Colombia: a RENEHOC-PETHEMA studySemantic proximity Read ↗

How I treat mixed-phenotype acute leukemiaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.